This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.

HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.

This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.




To see our most recent news,
follow us on LinkedIn

Go to our LinkedIn page